Literature DB >> 6974704

Adoptive transfer of immunity induced by semi-allogeneic hybrid cells, against a murine fibrosarcoma.

B Payelle, M F Poupon, G Lespinats.   

Abstract

Semi-allogeneic somatic hybrid cells derived from the fusion of a C57BL/6 fibrosarcoma (MCB6-1) and A9 cells (C3H origin) were used to immunize C57BL/6 mice against the parental tumor cells. These hybrid cells expressed H-2 histocompatibility antigen of both parental cells (H-2b and H-2k), and failed to produce tumors in normal C57BL/6 mice. A single i.p. injection of hybrid cells induced anti-tumor immunity which could be transferred to normal C57BL/6 recipient mice by immune spleen or peritoneal cells; the efficient cells were T cells, as this activity was completely abrogated by treatment with anti-Thy-1-2 antiserum and complement. Among immune splenic T cells, only the light-density T cells, obtained after fractionation on Percoll gradient, were effective in the transfer of immunity. Immunity induced by the hybrid cells was specific for MCB6-1 parental tumor cells. This immunity could be transferred during two brief periods, 7 to 12 days, and 40 to 50 days, after hybrid cell injection; there appeared to be an intermediate period, 12 to 40 days after immunization, during which no immunity could be transferred. These results suggest a suppressive mechanism implicated during hybrid cell immunization and interacting with the anti-tumor immune response.

Entities:  

Mesh:

Year:  1981        PMID: 6974704     DOI: 10.1002/ijc.2910270609

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  Suppressor T cells in BCG-treated mice interfere with an in vivo specific antitumoral immune response.

Authors:  B Payelle; M Brulay-Rosset; M F Poupon; G Lespinats
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

2.  Semi-allogeneic vaccine for T-cell lymphoma.

Authors:  Jin Yu; Mark S Kindy; Sebastiano Gattoni-Celli
Journal:  J Transl Med       Date:  2007-08-08       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.